{"component": "definition", "props": {"groups": [{"snippet": "means any Patents owned or Controlled by Isis.", "snippet_links": [{"key": "owned-or-controlled", "type": "definition", "offset": [18, 37]}], "size": 23, "samples": [{"hash": "kYnOyh52Jb2", "uri": "/contracts/kYnOyh52Jb2#isis-patent-rights", "label": "Collaboration and Co Development Agreement (Oncogenex Technologies Inc)", "score": 21.0, "published": true}, {"hash": "jTjSIeGcG9J", "uri": "/contracts/jTjSIeGcG9J#isis-patent-rights", "label": "Collaboration and License Agreement (Oncogenex Technologies Inc)", "score": 21.0, "published": true}, {"hash": "iI67wReCMKk", "uri": "/contracts/iI67wReCMKk#isis-patent-rights", "label": "Collaboration and Co Development Agreement (Isis Pharmaceuticals Inc)", "score": 21.0, "published": true}], "hash": "0f406a62637d4a5b3312483800d03d42", "id": 1}, {"snippet": "means Isis Current Motif and Mechanism Patents, Isis Future Motif and Mechanism Patents, Isis Current Chemistry Patents and Isis Future Chemistry Patents.", "snippet_links": [{"key": "isis-current-motif-and-mechanism-patents", "type": "definition", "offset": [6, 46]}, {"key": "isis-future-motif-and-mechanism-patents", "type": "definition", "offset": [48, 87]}, {"key": "isis-current-chemistry-patents", "type": "definition", "offset": [89, 119]}, {"key": "isis-future-chemistry-patents", "type": "definition", "offset": [124, 153]}], "size": 9, "samples": [{"hash": "5mTicnhOZ59", "uri": "/contracts/5mTicnhOZ59#isis-patent-rights", "label": "License and Collaboration Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 22.1307323751, "published": true}, {"hash": "absHN1ffB62", "uri": "/contracts/absHN1ffB62#isis-patent-rights", "label": "License and Collaboration Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 21.0, "published": true}, {"hash": "ftWqbOkVaZn", "uri": "/contracts/ftWqbOkVaZn#isis-patent-rights", "label": "Strategic Collaboration and License Agreement (Alnylam Pharmaceuticals Inc)", "score": 18.0, "published": true}], "hash": "5930e09f1b0bc441d941504c948d86dd", "id": 2}, {"snippet": "means all rights in Patents owned by ISIS that are within the ISIS Core Technology Patent Rights, the Manufacturing Patent Rights, the ISIS Formulation Patent Rights, or the Research Target Patent Rights.", "snippet_links": [{"key": "all-rights", "type": "clause", "offset": [6, 16]}, {"key": "patents-owned-by", "type": "definition", "offset": [20, 36]}, {"key": "isis-core-technology-patent-rights", "type": "definition", "offset": [62, 96]}, {"key": "manufacturing-patent-rights", "type": "definition", "offset": [102, 129]}, {"key": "formulation-patent", "type": "definition", "offset": [140, 158]}, {"key": "target-patent-rights", "type": "definition", "offset": [183, 203]}], "size": 5, "samples": [{"hash": "9IVczAjtoR1", "uri": "/contracts/9IVczAjtoR1#isis-patent-rights", "label": "Collaboration and License Agreement (Isis Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "2u97yFVsPXY", "uri": "/contracts/2u97yFVsPXY#isis-patent-rights", "label": "Collaboration and License Agreement (Isis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "g6C4tyWWSLw", "uri": "https://ir.ionispharma.com/static-files/2aee22c9-591f-42e9-8781-b09ca754fc5b", "label": "ir.ionispharma.com", "score": 9.9637234771, "published": false}], "hash": "87037872a960ae607562bef71449bf3e", "id": 3}, {"snippet": "means the Isis Core Technology Patent Rights, the Isis Manufacturing Patent Rights, the Isis Blocking Patent Rights and Isis ASO Compound Patent Rights. To the extent Isis Controls Patent Rights as of the Effective Date or during the Collaboration Term other than the Isis Manufacturing Patents, Isis Core Technology Patent Rights, Isis Blocking Patent Rights and the Isis ASO Compound Patent Rights, and such Patent Rights would Cover a Lilly ASO Product, such Patent Rights will be included in the definition of Isis Patent Rights automatically if they can be licensed to Lilly with no obligation (financial or otherwise) to any Third Party with respect to a particular Lilly ASO Product at the time the Lilly ASO Product is licensed from Isis, or if the relevant invention is made subsequent to such license, at the time such invention is made. To the extent Isis Controls Patent Rights as of the Effective Date or during the Collaboration Term, other than the Isis Manufacturing Patent Rights, the Isis Core Technology Patent Rights, Isis Blocking Patent Rights and Isis ASO Compound Patent Rights that would Cover a Lilly ASO Product, and such Patent Rights were acquired by Isis from a Third Party and/or Isis has obligations (financial or otherwise) to a Third Party in connection with the practice of such Patent Rights, such Patent Rights will only be included in the definition of Isis Patent Rights if Isis and Lilly negotiate an agreement to license such Patent Rights which includes (1) the assumption by Lilly of all financial obligations of Isis arising from the grant to Lilly and the practice by Lilly, its Affiliates of Sublicensees, of the Patent Rights, (2) the compensation", "snippet_links": [{"key": "isis-core-technology-patent-rights", "type": "definition", "offset": [10, 44]}, {"key": "isis-manufacturing-patent-rights", "type": "definition", "offset": [50, 82]}, {"key": "isis-blocking-patent-rights", "type": "definition", "offset": [88, 115]}, {"key": "isis-aso-compound-patent-rights", "type": "definition", "offset": [120, 151]}, {"key": "to-the-extent", "type": "clause", "offset": [153, 166]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [195, 219]}, {"key": "collaboration-term", "type": "clause", "offset": [234, 252]}, {"key": "isis-manufacturing-patents", "type": "definition", "offset": [268, 294]}, {"key": "lilly-aso-product", "type": "definition", "offset": [438, 455]}, {"key": "the-definition-of", "type": "definition", "offset": [496, 513]}, {"key": "no-obligation", "type": "definition", "offset": [585, 598]}, {"key": "with-respect-to", "type": "clause", "offset": [643, 658]}, {"key": "at-the-time", "type": "clause", "offset": [690, 701]}, {"key": "the-relevant", "type": "clause", "offset": [753, 765]}, {"key": "a-third-party", "type": "clause", "offset": [1190, 1203]}, {"key": "in-connection-with", "type": "clause", "offset": [1274, 1292]}, {"key": "the-practice", "type": "clause", "offset": [1293, 1305]}, {"key": "agreement-to-license", "type": "clause", "offset": [1441, 1461]}, {"key": "by-lilly", "type": "clause", "offset": [1515, 1523]}, {"key": "obligations-of", "type": "clause", "offset": [1541, 1555]}, {"key": "grant-to-lilly", "type": "clause", "offset": [1578, 1592]}, {"key": "the-patent", "type": "definition", "offset": [1655, 1665]}, {"key": "the-compensation", "type": "clause", "offset": [1678, 1694]}], "size": 4, "samples": [{"hash": "fVCGWc3h7gT", "uri": "/contracts/fVCGWc3h7gT#isis-patent-rights", "label": "Collaboration Agreement (Isis Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "jRj1jZRaHQz", "uri": "https://ir.ionispharma.com/static-files/3e2f9b7f-0ea0-4b08-bae5-7432d83a9103", "label": "ir.ionispharma.com", "score": 9.6707734428, "published": false}], "hash": "9fef532f0c7974e3fa9c799c67e582ca", "id": 4}, {"snippet": "means any and all patents and patent", "snippet_links": [{"key": "all-patents", "type": "clause", "offset": [14, 25]}], "size": 2, "samples": [{"hash": "1iEJq0xlHJs", "uri": "https://ir.ionis.com/static-files/9a411f92-c822-45b5-ab66-33a6ae1b6427", "label": "ir.ionis.com", "score": 12.7373656825, "published": false}, {"hash": "lzqQaEbyWma", "uri": "https://ir.ionispharma.com/static-files/1b84d3cd-65fc-482d-bdec-13a0ab14983d", "label": "ir.ionispharma.com", "score": 9.9650924025, "published": false}], "hash": "38480db665c94bab9e2034c2fb179d3e", "id": 5}, {"snippet": "means Isis Current Motif and Mechanism Patents, Isis Future Motif and Mechanism Patents, Isis Current Chemistry Patents and Isis Future Chemistry Patents. For purposes of determining whether a royalty is payable by Alnylam under Section 7.2 in connection with the sale of an Alnylam Single Stranded RNAi Product, any Joint Patent, a Valid Claim of which covers the manufacture, use or sale of such Alnylam Single Stranded RNAi Product, will be considered an Isis Patent Right.", "snippet_links": [{"key": "isis-current-motif-and-mechanism-patents", "type": "definition", "offset": [6, 46]}, {"key": "isis-future-motif-and-mechanism-patents", "type": "definition", "offset": [48, 87]}, {"key": "isis-current-chemistry-patents", "type": "definition", "offset": [89, 119]}, {"key": "isis-future-chemistry-patents", "type": "definition", "offset": [124, 153]}, {"key": "for-purposes-of", "type": "clause", "offset": [155, 170]}, {"key": "by-alnylam", "type": "clause", "offset": [212, 222]}, {"key": "section-72", "type": "clause", "offset": [229, 240]}, {"key": "in-connection-with", "type": "clause", "offset": [241, 259]}, {"key": "sale-of", "type": "clause", "offset": [264, 271]}, {"key": "single-stranded-rnai-product", "type": "definition", "offset": [283, 311]}, {"key": "joint-patent", "type": "definition", "offset": [317, 329]}, {"key": "a-valid-claim", "type": "clause", "offset": [331, 344]}, {"key": "patent-right", "type": "clause", "offset": [463, 475]}], "size": 2, "samples": [{"hash": "jSRib1UcC3f", "uri": "https://ir.ionispharma.com/static-files/14abb88a-3b91-422e-8137-39e430784197", "label": "ir.ionispharma.com", "score": 9.9637234771, "published": false}, {"hash": "Go1NczM8dO", "uri": "https://ir.ionispharma.com/static-files/fa960853-a1ba-4437-80d9-1fc8f60fc2ca", "label": "ir.ionispharma.com", "score": 9.6707734428, "published": false}], "hash": "6bd812105af12b37bf5bc273005980ac", "id": 6}, {"snippet": "means any and all patents and patent applications in the Territory (which for the purposes of this Agreement shall be deemed to include certificates of invention and applications for certificates of invention) which during the term of this Agreement are owned by ISIS or to which ISIS through license or otherwise acquires rights which (a) claim, cover or relate to Compound and/or Product including without limitation those patents and patent applications which (i) are Compound patents and patent applications listed on Schedule 1.16 (a) (i); or (ii) are ISIS Core Technology patents and patent applications listed on Schedule 1.16 (a) (ii) (to the extent that such ISIS Core Technology patents and patent applications are necessary or useful to Merck in the Field) and patents and patent applications which claim, cover or relate to Core Technology Improvements (to the extent that such Core Technology Improvement patents and patent applications are necessary to Merck to practice effectively in the Field) ; or iii) are ISIS Manufacturing Technology patents and patent applications listed on Schedule 1.16 (a) (iii) (to the extent that such ISIS Manufacturing Technology patents and patent applications are necessary or useful to Merck in the Field) and patents and patent applications which claim, cover or relate to Manufacturing Technology Improvements, to the extent that such Manufacturing Technology Improvement patents and patent applications are necessary or useful to Merck in the Field; or (b) are divisions, continuations, continuations-in-part, reissues, renewals, extensions, supplementary protection certificates, and the like of any of the foregoing patents and patent applications and foreign equivalents thereof.", "snippet_links": [{"key": "patents-and-patent-applications", "type": "definition", "offset": [18, 49]}, {"key": "in-the-territory", "type": "clause", "offset": [50, 66]}, {"key": "for-the-purposes-of-this-agreement", "type": "clause", "offset": [74, 108]}, {"key": "applications-for", "type": "clause", "offset": [166, 182]}, {"key": "during-the-term-of-this-agreement", "type": "clause", "offset": [216, 249]}, {"key": "owned-by", "type": "definition", "offset": [254, 262]}, {"key": "relate-to", "type": "definition", "offset": [356, 365]}, {"key": "including-without-limitation", "type": "clause", "offset": [390, 418]}, {"key": "compound-patents", "type": "definition", "offset": [471, 487]}, {"key": "on-schedule", "type": "definition", "offset": [519, 530]}, {"key": "isis-core-technology-patents", "type": "definition", "offset": [557, 585]}, {"key": "to-the-extent", "type": "clause", "offset": [644, 657]}, {"key": "in-the-field", "type": "clause", "offset": [754, 766]}, {"key": "core-technology-improvements", "type": "clause", "offset": [836, 864]}, {"key": "improvement-patents", "type": "definition", "offset": [906, 925]}, {"key": "to-practice", "type": "clause", "offset": [973, 984]}, {"key": "isis-manufacturing-technology", "type": "definition", "offset": [1025, 1054]}, {"key": "manufacturing-technology-improvement", "type": "definition", "offset": [1386, 1422]}, {"key": "supplementary-protection-certificates", "type": "clause", "offset": [1594, 1631]}, {"key": "the-foregoing", "type": "definition", "offset": [1656, 1669]}], "size": 2, "samples": [{"hash": "a702SfsGpx9", "uri": "/contracts/a702SfsGpx9#isis-patent-rights", "label": "Development and License Agreement (Isis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "QI3CkQsJe0", "uri": "/contracts/QI3CkQsJe0#isis-patent-rights", "label": "Development and License Agreement (Isis Pharmaceuticals Inc)", "score": 18.0, "published": true}], "hash": "4ed34a5fedd0426786b3261a4feb625f", "id": 7}, {"snippet": "has the meaning assigned thereto in the Isis License Agreement.", "snippet_links": [{"key": "isis-license-agreement", "type": "definition", "offset": [40, 62]}], "size": 1, "samples": [{"hash": "6NmrqF8VPHq", "uri": "/contracts/6NmrqF8VPHq#isis-patent-rights", "label": "Subscription, Joint Development and Operating Agreement (Isis Pharmaceuticals Inc)", "score": 18.0, "published": true}], "hash": "8f6e36cf9a49867ab94812ae756f6ac8", "id": 8}, {"snippet": "means the Isis Core Technology Patent Rights, the Isis Manufacturing Patent Rights, the Isis Blocking Patent Rights and Isis ASO Compound Patent Rights. To the extent Isis Controls Patent Rights as of the Effective Date or during the Collaboration Term other than the Isis Manufacturing", "snippet_links": [{"key": "isis-core-technology-patent-rights", "type": "definition", "offset": [10, 44]}, {"key": "isis-manufacturing-patent-rights", "type": "definition", "offset": [50, 82]}, {"key": "isis-blocking-patent-rights", "type": "definition", "offset": [88, 115]}, {"key": "isis-aso-compound-patent-rights", "type": "definition", "offset": [120, 151]}, {"key": "to-the-extent", "type": "clause", "offset": [153, 166]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [195, 219]}, {"key": "collaboration-term", "type": "clause", "offset": [234, 252]}], "size": 1, "samples": [{"hash": "9bNvQaTA5EQ", "uri": "https://ir.ionispharma.com/static-files/27c1c7c6-e6f3-4760-84f9-1f78d017e7b9", "label": "ir.ionispharma.com", "score": 9.9650924025, "published": false}], "hash": "4524acc6b4ca7062eab94b81d8c9dd85", "id": 9}, {"snippet": "means the Isis Core Technology Patent Rights, the Isis Manufacturing Patent Rights and Isis ASO Compound Patent Rights. To the extent Isis Controls Patent Rights as of the Effective Date other than the Isis Manufacturing Patents, Isis Core Technology Patent Rights, and the Isis ASO Compound Patent Rights, and such Patent Rights would Cover a Product, such Patent Rights will be included in the definition of Isis Patent Rights automatically if they can be licensed to Lilly with no obligation (financial or otherwise) to any Third Party with respect to a Product. To the extent Isis Controls Patent Rights as of the Effective Date, other than the Isis Manufacturing Patent Rights, the Isis Core Technology Patent Rights and Isis ASO Compound Patent Rights that would Cover a Lilly ASO Product, and such Patent Rights were acquired by Isis from a Third Party and/or Isis has obligations (financial or otherwise) to a Third Party in connection with the practice of such Patent Rights, such Patent Rights will only be included in the definition of Isis Patent Rights if Isis and Lilly negotiate an agreement to license such Patent Rights which includes (1) the assumption by Lilly of all financial obligations of Isis arising from the grant to Lilly and the practice by Lilly, its Affiliates of Sublicensees, of the Patent Rights, (2) the compensation of an appropriate portion of any acquisition costs incurred by Isis in connection with obtaining Control of such Patent Rights, and (3) an agreement by Lilly to abide by all of the terms of the agreement under which Isis has obtained Control of such Patent Right. For purposes of determining whether a royalty is payable under Section 4.4 Isis Patent Rights will include any Patent Right assigned to Lilly under Section 7.2.", "snippet_links": [{"key": "isis-core-technology-patent-rights", "type": "definition", "offset": [10, 44]}, {"key": "isis-manufacturing-patent-rights", "type": "definition", "offset": [50, 82]}, {"key": "isis-aso-compound-patent-rights", "type": "definition", "offset": [87, 118]}, {"key": "to-the-extent", "type": "clause", "offset": [120, 133]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [162, 186]}, {"key": "isis-manufacturing-patents", "type": "definition", "offset": [202, 228]}, {"key": "the-definition-of", "type": "definition", "offset": [392, 409]}, {"key": "no-obligation", "type": "definition", "offset": [481, 494]}, {"key": "with-respect-to", "type": "clause", "offset": [539, 554]}, {"key": "lilly-aso-product", "type": "definition", "offset": [777, 794]}, {"key": "a-third-party", "type": "clause", "offset": [846, 859]}, {"key": "in-connection-with", "type": "clause", "offset": [930, 948]}, {"key": "the-practice", "type": "clause", "offset": [949, 961]}, {"key": "agreement-to-license", "type": "clause", "offset": [1097, 1117]}, {"key": "by-lilly", "type": "clause", "offset": [1171, 1179]}, {"key": "obligations-of", "type": "clause", "offset": [1197, 1211]}, {"key": "grant-to-lilly", "type": "clause", "offset": [1234, 1248]}, {"key": "the-patent", "type": "definition", "offset": [1311, 1321]}, {"key": "the-compensation", "type": "clause", "offset": [1334, 1350]}, {"key": "an-appropriate", "type": "clause", "offset": [1354, 1368]}, {"key": "costs-incurred", "type": "definition", "offset": [1396, 1410]}, {"key": "control-of", "type": "definition", "offset": [1448, 1458]}, {"key": "the-terms-of-the-agreement", "type": "clause", "offset": [1528, 1554]}, {"key": "for-purposes-of", "type": "clause", "offset": [1615, 1630]}, {"key": "section-44", "type": "clause", "offset": [1678, 1689]}, {"key": "section-72", "type": "clause", "offset": [1763, 1774]}], "size": 1, "samples": [{"hash": "itxWMAkw80k", "uri": "/contracts/itxWMAkw80k#isis-patent-rights", "label": "Drug Development and License Option Agreement (Isis Pharmaceuticals Inc)", "score": 21.1615331964, "published": true}], "hash": "aa10e152c4c133947ed4dab1d22af40b", "id": 10}], "next_curs": "Cl8SWWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjsLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIbaXNpcy1wYXRlbnQtcmlnaHRzIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"snippet": "means any Patents owned or Controlled by Isis.", "title": "Isis Patent Rights", "size": 52, "id": "isis-patent-rights", "examples": ["Alnylam shall use good faith efforts to include sublicenses under the licenses under the <strong>Isis Patent Rights</strong> granted to Alnylam in Sections 5.1(a) and 5.1(b) in any Third Party collaboration or license agreement in which Alnylam grants rights to develop and commercialize Double Stranded RNA Products, unless the technology covered by such licensed <strong>Isis Patent Rights</strong> would not reasonably be expected to advance the goals of such Third Party collaboration or license relationship.", "Isis will, subject to Section 7.2.3 and Section 7.2.5, have the sole right, at its cost and expense and at its sole discretion, to obtain, prosecute and maintain throughout the world the <strong>Isis Patent Rights</strong>.", "With respect to <strong>Isis Patent Rights</strong> or OncoGenex Patent Rights, and subject to Section 7.3.1(b), the owner of such Patents will have the sole right, but not the obligation, at its own expense, to remove such infringement using commercially appropriate steps, including the filing of an infringement suit or taking other similar action, and the other Party will have the right, at its own expense, to be represented in any such action.", "Isis will have the sole right, at its cost and expense and at its sole discretion, to obtain, prosecute and maintain throughout the world the <strong>Isis Patent Rights</strong>, including, but not limited to the Isis Core Technology Patents and the Isis Manufacturing Patents, but excluding the Product-Specific Technology Patents and the Joint Patents.", "If any Third Party asserts in writing or in any legal proceeding that any of the <strong>Isis Patent Rights</strong> are unenforceable based on any term or condition of this Agreement, the Parties shall amend this Agreement as may reasonably be required to effect the original intent of the Parties, including to preserve the enforceability of such <strong>Isis Patent Rights</strong>.", "All rights in and to <strong>Isis Patent Rights</strong> and Isis Know-How not expressly licensed to Akcea under this Agreement are hereby retained by Isis or its Affiliates.", "Alnylam shall use good faith efforts to include sublicenses under the licenses under the <strong>Isis Patent Rights</strong> granted to Alnylam in Sections 5.1(a) in any Third Party collaboration or license agreement in which Alnylam grants rights to develop and commercialize Double Stranded RNA Products, unless the technology covered by such licensed <strong>Isis Patent Rights</strong> would not reasonably be expected to advance the goals of such Third Party collaboration or license relationship.", "If Alnylam grants a sublicense under the Isis Exclusive Target Patents where the Patents sublicensed thereunder include Patents that are also <strong>Isis Patent Rights</strong>, then such sublicense will be treated as a Bona Fide Discovery Collaboration for purposes of this Section 7.5(a) and Alnylam will pay Isis a percentage of Technology Access Fees received by Alnylam and its Affiliates in connection with such sublicense.", "OncoGenex covenants not to file any patent application with respect to the Product disclosing or claiming any information disclosed or claimed in the <strong>Isis Patent Rights</strong>, without Isis\u2019s prior written consent.", "To the best of Isis\u2019 knowledge, Isis is in compliance in all material respects with the material terms of all licenses and other agreements with Third Parties under which it has the right to use any <strong>Isis Patent Rights</strong>, all such agreements are in full force and effect, and no Third Party has given Isis written notice that an event has occurred which with notice or lapse of time would constitute a breach or default or permit termination, modification or acceleration under any such agreements."], "related": [["licensed-patent-rights", "Licensed Patent Rights", "Licensed Patent Rights"], ["program-patent-rights", "Program Patent Rights", "Program Patent Rights"], ["patent-rights", "Patent Rights", "Patent Rights"], ["joint-patent-rights", "Joint Patent Rights", "Joint Patent Rights"], ["collaboration-patent-rights", "Collaboration Patent Rights", "Collaboration Patent Rights"]], "related_snippets": [], "updated": "2025-07-07T00:35:48+00:00"}, "json": true, "cursor": ""}}